| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,750,000 |
| Market
Cap: |
373.45(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.85 - $24.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 10.2 |
| Insider 6 Months : 10.2 |
| Insider 3/6 Months : 20.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
28,800 |
28,800 |
46,900 |
321,025 |
| Total Buy Value |
$355,765 |
$355,765 |
$520,600 |
$4,296,022 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
6 |
6 |
10 |
34 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-10-16 |
2025-07-15 |
2025-01-14 |
2024-01-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Snehal |
CEO and CFO |
• • • |
2026-01-12 |
4 |
B |
$27.54 |
$79,866 |
D/D |
2,900 |
5,602,302 |
3.23 |
- |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-12-31 |
4 |
B |
$21.36 |
$91,848 |
D/D |
4,300 |
5,599,402 |
3.23 |
38% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-12-30 |
4 |
B |
$21.73 |
$63,017 |
D/D |
2,900 |
5,595,102 |
3.23 |
32% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-12-18 |
4 |
B |
$12.62 |
$51,742 |
D/D |
4,100 |
5,592,202 |
3.23 |
134% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-11-25 |
4 |
B |
$8.37 |
$38,502 |
D/D |
4,600 |
5,588,102 |
3.23 |
245% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-11-07 |
4 |
B |
$8.43 |
$89,358 |
D/D |
10,600 |
5,583,502 |
3.23 |
235% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-10-31 |
4 |
B |
$9.26 |
$21,298 |
D/D |
2,300 |
5,572,902 |
3.15 |
215% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-04-25 |
4 |
B |
$9.88 |
$35,568 |
D/D |
3,600 |
5,570,602 |
3.23 |
10% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-04-17 |
4 |
B |
$8.98 |
$48,492 |
D/D |
5,400 |
5,567,002 |
3.23 |
30% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-04-07 |
4 |
B |
$9.10 |
$32,760 |
D/D |
3,600 |
5,561,602 |
3.23 |
27% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-04-04 |
4 |
B |
$8.73 |
$48,015 |
D/D |
5,500 |
5,558,002 |
3.23 |
37% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-01-10 |
4 |
B |
$12.51 |
$31,275 |
D/D |
2,500 |
5,552,502 |
3.23 |
-21% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-01-07 |
4 |
B |
$13.75 |
$24,750 |
D/D |
1,800 |
5,550,002 |
3.15 |
-26% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-01-06 |
4 |
B |
$13.31 |
$14,641 |
D/D |
1,100 |
5,548,202 |
3.15 |
-26% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-01-03 |
4 |
B |
$12.95 |
$44,030 |
D/D |
3,400 |
5,547,102 |
3.23 |
-25% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2025-01-02 |
4 |
B |
$11.97 |
$23,940 |
D/D |
2,000 |
5,543,702 |
3.15 |
-20% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-12-31 |
4 |
B |
$11.36 |
$27,264 |
D/D |
2,400 |
5,541,702 |
3.23 |
-14% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-12-30 |
4 |
B |
$11.12 |
$35,584 |
D/D |
3,200 |
5,539,302 |
3.23 |
-12% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2024-11-21 |
4 |
B |
$12.91 |
$12,910 |
D/D |
1,000 |
264,148 |
2.74 |
-32% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-09-26 |
4 |
B |
$14.63 |
$21,945 |
D/D |
1,500 |
5,536,102 |
3.15 |
-13% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2024-08-12 |
4 |
B |
$13.85 |
$11,080 |
D/D |
800 |
263,148 |
2.74 |
-8% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-08-06 |
4 |
B |
$13.81 |
$27,620 |
D/D |
2,000 |
5,534,602 |
3.23 |
-5% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-08-05 |
4 |
B |
$13.18 |
$72,490 |
D/D |
5,500 |
5,532,602 |
3.23 |
-0% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2024-08-02 |
4 |
B |
$15.15 |
$15,150 |
D/D |
1,000 |
262,348 |
2.74 |
-7% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-07-23 |
4 |
B |
$15.89 |
$23,835 |
D/D |
1,500 |
5,527,102 |
3.15 |
-11% |
|
133 Records found
|
|
Page 1 of 6 |
|
|
0.27 (0.93%) 
